Tirofiban
- Generic Name
- Tirofiban
- Brand Names
- Aggrastat
- Drug Type
- Small Molecule
- Chemical Formula
- C22H36N2O5S
- CAS Number
- 144494-65-5
- Unique Ingredient Identifier
- GGX234SI5H
- Background
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
- Indication
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.
- Associated Conditions
- Cardiovascular Events
- Associated Therapies
- -
Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse
- Conditions
- Interventions
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Università degli Studi di Ferrara
- Target Recruit Count
- 100
- Registration Number
- NCT01336348
- Locations
- 🇮🇹
Cardiology Unit, Ferrara, Italy
Tirofiban and Enoxaparin in High Risk Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- The Prince Charles Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00790387
- Locations
- 🇦🇺
The Prince Charles Hospital, Brisbane, Queensland, Australia
Shanghai Registry of Acute Coronary Events
- Conditions
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 20000
- Registration Number
- NCT00713557
- Locations
- 🇨🇳
Dept. of Cardiology, Ruijin Hospital, Shanghai, Shanghai, China
The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2008-02-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00611169
Safety of High-dose Tirofiban During Coronary Angioplasty
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- S. Anna Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT00566891
- Locations
- 🇮🇹
S Anna Hospital, Catanzaro, Italy
GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 320
- Registration Number
- NCT00538317
- Locations
- 🇫🇷
Hospices Civils de Lyon, Lyon, France
Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2015-02-27
- Lead Sponsor
- Hospital Avicenne
- Target Recruit Count
- 170
- Registration Number
- NCT00445263
- Locations
- 🇫🇷
Samu 93 - Chu Avicenne, Bobigny, Ile de France, France
The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention
- Conditions
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- Jordan Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT00407771
- Locations
- 🇯🇴
Jordan Hospital, Amman, Jordan
Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance
- Conditions
- Interventions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2011-07-01
- Lead Sponsor
- Università degli Studi di Ferrara
- Target Recruit Count
- 263
- Registration Number
- NCT00398463
- Locations
- 🇮🇹
Cattedra di Cardiologia, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Fe, Italy
Treating Acute MI Patients With Aggrastat on Their Way to Hospital
- Conditions
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2011-08-11
- Lead Sponsor
- The Baruch Padeh Medical Center, Poriya
- Target Recruit Count
- 200
- Registration Number
- NCT00300833
- Locations
- 🇮🇱
Magen David ,, Tiberias, Israel
🇮🇱Cardiovascular Division, The Baruch Padeh Medical Center, Poriya,, Tiberias, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.